RYTM

Rhythm Pharmaceuticals reported a Q3 loss of $0.61 per share, beating consensus estimates of $0.68 loss, with a 10.29% earnings surprise. Revenue reached $92.13 million, surpassing estimates by 9.07% and nearly doubling year-ago revenues of $51.3 million.

However, the stock has underperformed the market, down 12.7% year-to-date versus the S&P 500's 10.2% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Rhythm Pharmaceuticals (RYTM) is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +1.38% and Zacks Rank #3. The company is projected to report a quarterly loss of $0.68 per share (improved from $0.81 year-ago) with revenues of $84.47 million, up 64.7% year-over-year. The stock has beaten consensus EPS estimates in 3 of the last 4 quarters.

Rhythm Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months (up 8.5%). The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improving business fundamentals and institutional investor buying pressure.